We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.

The Federal debt in 1965 was $322.3 billion. In 2025 it is at $36.24 trillion. The unemployment rate was 5.2%. Now it is at 4.1%.

On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these spaces.

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

The technical aspect of DeepSeek is not new. The reaction to it though, is new. 

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

Transportation IYT chart is incredible. The price action Friday showed the attempt to take out the January trend trade range and then failed.  

Sugar, as shown in the weekly chart, has broken down under the 200-WMA for the first time since December 2020. However, it is holding the August 2024 low.  

As long as XRT holds 78.00, it’s back where it broke out from after a massive consolidation last year. 

Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY.

The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.

Russell 2000 IWM, has a few key points of support to hold. $217 is one. The 50-week moving average at around $212.45 is another.

Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December.

​​​​​​​As we ended this week, clearly Nasdaq held up better than pretty much everything else. 

Retail XRT should hold the gap up it started this past week with. If that is the case, we anticipate a move higher for the coming week. 

Biotech stocks are poised for a recovery in a seasonally strong period through January 2025.

What we waited for was a weekly close over 79.20, a level we have not seen since February 2022. 

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

On CNBC's "Halftime Report Final Trades," Tim Seymour of Seymour Asset Management picked Cameco Corporation.

XRT failed to rally above the $80 level, the top of the 10-month consolidation.

KRE is back to the scene of the crime at the 65 level. Above there, we see 75 area as the next resistance.

Considering where the Economic Modern Family was just a few weeks ago, clearly euphoria has spread since the election.

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

As the SPY corrects a bit from the recent run up to all-time highs, we still have keen eyes on other sectors.